← Back to Home

FDA Clears At-Home Starter Dose of Leqembi, Moving Alzheimer’s Treatment Further Beyond the Clinic

The significance of this approval is not a new drug name, but the reshaping of the treatment process: if early Alzheimer’s patients can use subcutaneous injection from the initiation stage, the accessibility, monitoring burden, and allocation of medical resources for anti-amyloid therapies will all have to be recalculated.

By SURL BioNews

Competition among anti-Alzheimer’s drugs is moving from whether they can clear pathological proteins in the brain to another question closer to daily life: how patients can receive treatment over the long term. PharmaLive reported that the U.S. Food and Drug Administration has approved an at-home starter-dose version of Eisai and Biogen’s Alzheimer’s drug Leqembi, further extending the use setting of this anti-amyloid antibody from infusion centers to patients’ homes.

Leqembi’s main ingredient is lecanemab, which targets soluble and insoluble amyloid protein aggregates in the brains of patients with early Alzheimer’s disease. Treatment previously centered on intravenous infusion once every two weeks. Patients not only had to visit medical institutions regularly, but also had to cooperate with imaging examinations and safety monitoring. If the subcutaneous injection version for the initiation stage has indeed been approved, it means regulators have accepted not only the drug itself, but also a more simplified route of administration.

This progress builds on the prior regulatory foundation for the subcutaneous formulation. Eisai announced in 2025 that the FDA had approved LEQEMBI IQLIK as a maintenance-dose option for early Alzheimer’s disease; the autoinjector contains 360 mg/1.8 mL of drug solution, is administered by subcutaneous injection once weekly, and takes about 15 seconds to inject. At the time, the approval applied to patients who had completed 18 months of intravenous infusion therapy once every two weeks, allowing them to switch between intravenous maintenance treatment once every four weeks and weekly subcutaneous injection.

If this approval extends to an at-home starter dose, its significance is that patients may not have to first undergo a lengthy in-clinic infusion period before gaining access to a more convenient method of administration. Investor’s Business Daily had also previously noted that Eisai and Biogen planned to promote the subcutaneous version as a more front-line use option; this aligns with the commercial and clinical logic of drugmakers seeking to reduce pressure on infusion centers and improve access for patients in remote areas and those with limited mobility.

However, a simpler method of administration does not mean the treatment itself becomes lightweight. Leqembi is an antibody therapy that affects amyloid deposits in the brain, and its use still involves brain imaging, confirmation of amyloid pathology, and monitoring for risks related to ARIA and other brain edema or microhemorrhage. At-home administration can shorten injection time, but it cannot eliminate physician evaluation, patient screening, and safety follow-up.

Eisai previously said the approval of the subcutaneous maintenance dose came from a subcutaneous substudy in the Phase 3 Clarity AD open-label extension study, with safety data covering more than 600 patients. These data support switching the route of administration for maintenance treatment; as for the full review basis, label details, and applicable conditions for the starter-dose version, these still need to be based on the FDA label and the company’s official information, and its clinical scope cannot be inferred solely from brief reports.

At the market level, the shift of Leqembi toward subcutaneous administration also reflects that Alzheimer’s drugs are entering competition around long-term care processes. For hospitals, one fewer infusion may free up equipment and staff; for patients and caregivers, one fewer round trip to a medical institution may mean a more sustainable treatment arrangement. But whether it can truly improve utilization will still depend on insurance coverage, diagnostic capacity, imaging-monitoring arrangements, and clinicians’ grasp of the safety boundaries for at-home administration.

References

  1. PharmaLive
  2. Eisai Co., Ltd.
  3. Investor's Business Daily